Results 231 to 240 of about 1,133,085 (338)

A Longitudinal Study of the Impact of R&D, Patents, and Product Innovation on Firm Performance

, 2010
Kendall Artz, Patricia M. Norman, Donald E. Hatfield, Laura B. Cardinal   +3 more
semanticscholar   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

From mechanisms to anti-fibrotic drugs in hepatic stellate cell research: a global bibliometric analysis with patent and clinical perspectives (2000-2025). [PDF]

Front Pharmacol
Mao X, Chen P, Wubur P, Liu Y, Zhao Y, Zhang S, Guan N, Li B.   +7 more
europepmc   +1 more source

Intellectual Property Patent Registration for the Protection of Your Data (IPPR)

Editor-in-Chief, Edison Carrasco-Jiménez   +1 more
openalex   +1 more source

Ön eğitimli Bert modeli ile patent sınıflandırılması

Selen Yücesoy Kahraman, Alptekin Durmuşoğlu, Türkay Dereli   +2 more
openalex   +2 more sources

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Monoclonal antibody formulations: a quantitative analysis of marketed products and patents. [PDF]

MAbs
Peng Y, Lyu L, Chen S, Ning B, Li C, Wu CY, Hu Y.   +6 more
europepmc   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

The EAES intellectual property protection guide. [PDF]

Surg Endosc
Nakajima K, Manfredi L, Yoshida E, Horeman T, Mintz Y.   +4 more
europepmc   +1 more source

Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes

, 2017
Melissa Liebowitz, Ronald I. Clyman
openalex   +2 more sources